Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"

The pharmaceutical firm thinks Lu AG0922 could be the backbone of a new generation of migraine treatments and has launched several studies in the hope of targeting a broader indication, Head of R&D at Lundbeck Johan Luthman tells MedWatch.

Johan Luthman, head of Research and Development at Lundbeck | Photo: PR / Lundbeck

Pharmaceutical firm Lundbeck's Laboratories are buzzing, busy with the work spearheaded by the company's Head of Research and Development Johan Luthman, as a new generation of migraine drugs are taking shape.

After Lundbeck acquired Alder Biopharmaceuticals in 2019 for USD 1.95bn in 2019, migraine treatment has become one of Lundbeck's biggest focus areas. Since then, the migraine preventive treatment, Vyepti, has reached the market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs